清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

医学 耐受性 内科学 肺癌 药效学 吉非替尼 肿瘤科 不利影响 危险系数 表皮生长因子受体 实体瘤疗效评价标准 非小细胞肺癌 胃肠病学 药代动力学 癌症 临床研究阶段 毒性 置信区间 A549电池
作者
Ben Creelan,Tammie C. Yeh,S.-W. Kim,Naoyuki Nogami,D.-W. Kim,Laura Q. Chow,Shintaro Kanda,Rosie Taylor,Weifeng Tang,Min Tang,Helen K. Angell,Martine P. Roudier,Marcelo Marotti,Don L. Gibbons
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:30: ii31-ii32 被引量:11
标识
DOI:10.1093/annonc/mdz067.001
摘要

Background: G and D have both shown efficacy in patients (pts) with NSCLC; G + D may improve durability of response. Methods: This Phase 1 dose escalation (Part A) and expansion (Part B) study (NCT0208811) assessed G 250 mg once daily + D 3 mg/kg (Part A) or 10 mg/kg (Parts A + B) every 2 weeks in pts with locally advanced/metastatic NSCLC. Part A pts were all comers who had failed to respond/relapsed following standard treatment (Tx). Part B pts had sensitising EGFR mutations and were tyrosine kinase inhibitor naïve: Arms 1 + 1a received G + D; Arm 2 received G (4 weeks) before G + D. Primary objective: safety/tolerability. Secondary objectives: pharmacokinetics (PK), pharmacodynamics, immunogenicity (anti-drug antibodies [ADAs]) and efficacy. Exploratory objective: evaluation of biomarkers (e.g. tumour programmed cell death ligand-1 [PD-L1]) and relationship with efficacy. Results: There were no dose limiting toxicities in Part A (n = 16) and D 10 mg/kg was used in Part B. In Part B (n = 40) all pts had possible Tx related adverse events (TRAEs; Table): diarrhoea (68%) and elevated alanine aminotransferase (ALT; 58%) were the most common TRAEs; elevated ALT (20%) and aspartate aminotransferase (15%) were the most common TRAEs leading to discontinuation. PK were as expected, inhibition of soluble PD-L1 was observed in all pts and no Tx emergent ADAs were observed. In Arms 1 + 1a, most patients achieved objective response (63.3%; 95% confidence intervals [CI]: 43.9, 80.1), median duration of response was 9.2 months (95% CI: 3.7, 14.0) and median progression-free survival (mPFS) was 10.1 months (95% CI: 5.5, 15.2; Table). PD-L1 expression ≥20% was associated with numerical improvements in mPFS (Table).Table84O Summary of safety, exposure, efficacy and exploratory analysesSafetyArm 1 (n = 10)Arm 1a (n = 20)Arm 2 (n = 10)Any grade AE, n (%)10 (100.0)20 (100.0)10 (100.0)Grade ≥3 AE, n (%)5 (50.0)15 (75.0)8 (80.0)Any grade TRAE, n (%)10 (100.0)20 (100.0)10 (100.0)Grade ≥3 TRAE, n (%)4 (40.0)11 (55.0)7 (70.0)Any grade TRAE leading to treatment discontinuation, n (%)010 (50.0)6 (60.0)Grade ≥3 TRAEaOne cycle equalled 28 days. leading to treatment discontinuation, n (%)09 (45.0)5 (50.0)ExposureArm 1 (n = 10)Arm 1a (n = 20)Arm 2 (n = 10)Median cyclesaOne cycle equalled 28 days. of D, n10.53.06.0Median total G treatment duration, months (min, max)12.0 (5, 13)5.7 (1, 12)7.1 (1, 13)EfficacyArm 1 (n = 10)Arm 1a (n = 20)Arm 2 (n = 10)Achieved OR, % (95% CI)80.0 (44.4, 97.5)55.0 (31.5, 76.9)70.0 (34.8, 93.3)Median DoR, months (95% CI)8.8 (3.0, 14.8)7.4 (3.7, 20.7)12.6 (5.5, 20.4)Median PFSbPatients with progression events: Arm 1, n = 9; Arm 1a, n = 16; Arm 2, n = 8; PD-L1 positive, n = 8; PD-L1 negative, n = 22., months (95% CI)10.5 (4.6, 17.0)9.3 (4.6, 15.2)12.0 (2.7, 15.6)PD-L1 statuscDetermined using fresh and archival baseline tumour biopsies (archival biopsies permitted in Arm 1a only) and SP263 Roche Tissue Diagnostics protocol: PD-L1 positivity was defined as tumour cell PD-L1 expression ≥20%; negative was defined as PD-L1 expression <20%. Results from Arms 1, 1a, and 2 were combined for this analysis.Positive (n = 12)Negative (n = 24)Median PFSbPatients with progression events: Arm 1, n = 9; Arm 1a, n = 16; Arm 2, n = 8; PD-L1 positive, n = 8; PD-L1 negative, n = 22., months (95% CI)15.9 (2.8, 21.3)9.1 (5.5, 11.9)HR (95% CI)0.461dHR was not statistically significant and should be interpreted with caution due to low patient numbers. AE, adverse event; CI, confidence interval; D, durvalumab; DoR, duration of response; G, gefitinib; HR, hazard ratio; max, maximum; min, minimum; n, number of patients; OR, objective response; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; TRAE, treatment-related adverse event. (0.187, 1.029)a One cycle equalled 28 days.b Patients with progression events: Arm 1, n = 9; Arm 1a, n = 16; Arm 2, n = 8; PD-L1 positive, n = 8; PD-L1 negative, n = 22.c Determined using fresh and archival baseline tumour biopsies (archival biopsies permitted in Arm 1a only) and SP263 Roche Tissue Diagnostics protocol: PD-L1 positivity was defined as tumour cell PD-L1 expression ≥20%; negative was defined as PD-L1 expression <20%. Results from Arms 1, 1a, and 2 were combined for this analysis.d HR was not statistically significant and should be interpreted with caution due to low patient numbers. AE, adverse event; CI, confidence interval; D, durvalumab; DoR, duration of response; G, gefitinib; HR, hazard ratio; max, maximum; min, minimum; n, number of patients; OR, objective response; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; TRAE, treatment-related adverse event. Open table in a new tab Conclusions: G + D had a high discontinuation rate due to liver related TRAEs and there was no additional benefit vs historical data for G alone. However, tumours expressing PD-L1 had favourable PFS and could be investigated further. Clinical trial identification: NCT02088112; March 14, 2014. Editorial acknowledgement: Medical writing support, under the direction of the authors, was provided by Lauren McNally, MSci, of CMC CONNECT, a division of McCann Health Medical Communications Ltd, Glasgow, UK, with funding from AstraZeneca PLC, in accordance with Good Publication Practice (GPP3) guidelines. Legal entity responsible for the study: MedImmune LLC (a wholly owned subsidiary of AstraZeneca PLC). Funding: AstraZeneca PLC. Disclosure: T. Yeh, W. Tang, M. Tang, H.K. Angell, M.P. Roudier, M. Marotti: Employee: AstraZeneca. R. Taylor: Employee, contractor: AstraZeneca. D.L. Gibbons: Advisory boards/research funding: AstraZeneca. All other authors have declared no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yuan完成签到,获得积分10
3秒前
害羞傲安完成签到,获得积分10
4秒前
夏月虚闲完成签到,获得积分10
5秒前
huan完成签到,获得积分10
6秒前
坦率钢笔完成签到,获得积分10
6秒前
yuxuan1完成签到,获得积分10
7秒前
刘沂卓完成签到,获得积分10
7秒前
suda完成签到,获得积分10
9秒前
是丹小朱呀完成签到,获得积分10
9秒前
美满的水卉完成签到,获得积分10
9秒前
MIO完成签到,获得积分10
10秒前
10秒前
皮卡皮卡皮卡丘完成签到,获得积分10
11秒前
yuxuan完成签到,获得积分10
11秒前
啵啵椰完成签到,获得积分10
17秒前
cxf完成签到,获得积分10
21秒前
Asumita完成签到,获得积分10
29秒前
强健的千柔完成签到,获得积分10
33秒前
可爱的函函的应助被York Chang采纳,获得10
33秒前
xzx完成签到,获得积分10
36秒前
41秒前
mayberichard完成签到,获得积分10
41秒前
冷傲的夜白完成签到,获得积分10
47秒前
无悔完成签到 ,获得积分0
48秒前
1分钟前
烂漫的诗蕊完成签到,获得积分10
1分钟前
儒雅的夏翠完成签到,获得积分10
1分钟前
幸福慕灵完成签到,获得积分10
1分钟前
羞涩的雨筠完成签到,获得积分10
1分钟前
阳光萝完成签到,获得积分10
1分钟前
1分钟前
黑熊精发布了新的文献求助10
1分钟前
深情的从丹完成签到,获得积分10
1分钟前
1437594843完成签到 ,获得积分10
1分钟前
黑熊精完成签到,获得积分10
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
xue完成签到 ,获得积分10
2分钟前
spinon完成签到,获得积分10
2分钟前
光亮豌豆完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179980
求助须知:如何正确求助?哪些是违规求助? 9570196
关于积分的说明 21808504
捐赠科研通 7775913
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557383
邀请新用户注册赠送积分活动 2478998